Cardiovascular Effects of an Immunosuppressive Agent Cyclosporin A [PDF]
International Journal of Immunopathology and Pharmacology, 2002 Cyclosporin A (CsA) is now routinely used for transplantation of all solid organs, bone marrow transplantation, and for an increasing number of immunological diseases. However, treatment with CsA is an important iatrogenic cause of post-transplant hypertension, hyperlipidemia, and diabetes, which may contribute to the high cardiovascular morbidity in ...
H. Sakamoto, M. Kurabayashi
openaire +3 more sources
Pleiotropic Effects of Calcium Channel Blockers [PDF]
, 2012 Clinical trials have reported reduced cardiovascular events with certain antihypertensive agents at a rate that could not be predicted by changes in brachial arterial pressure alone.
Mason, R. Preston
core +2 more sources
2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry [PDF]
, 2015 Objectives: Specifically we aim to demonstrate that the results of our earlier safety data hold true in this much larger multi-national and multi-ethnical population.
A Li +28 more
core +11 more sources
New antiplatelet agents for cardiovascular disease [PDF]
Canadian Medical Association Journal, 2013 Antiplatelet therapy is a key component in the management of many medical diseases to decrease the risk of cardiovascular events.[1][1] Acetylsalicyclic acid (ASA) is the most common antiplatelet agent used and is usually first-line therapy. Use of clopidogrel, especially in combination with ASA,
Cesilia Nishi, Doson Chua
openaire +3 more sources
BP Reduction, Kidney Function Decline, and Cardiovascular Events in Patients without CKD. [PDF]
, 2018 BACKGROUND AND OBJECTIVES: In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive systolic BP treatment (target
Dias, C +4 more
core +1 more source
Drug treatment of hypertension: focus on vascular health [PDF]
, 2016 Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C. +2 more
core +1 more source
Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease [PDF]
, 2012 <p>Aims: To compare the risk of vascular disease, HbA1c and weight change, between first prescribed insulins in people with type 2 diabetes.</p> <p>Methods: People included in THIN United Kingdom primary care record database who ...
A Wright +21 more
core +2 more sources
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
, 2012 In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding ...
Meade, Tom
core +1 more source
Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. [PDF]
, 2017 BackgroundThere is ongoing controversy regarding abacavir use in the treatment of HIV infection and the risk of subsequent development of cardiovascular disease.
Baxi, Sanjiv M +3 more
core +3 more sources
Interplay of integrins and selectins in metastasis
Molecular Oncology, EarlyView.Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva +2 more
wiley +1 more source